TFF Pharmaceuticals partners with Experic to expand manufacturing

26-Oct-2020 - Last updated on 26-Oct-2020 at 16:06 GMT

(photoman/iStock via Getty Images Plus)

The clinical-stage pharma firm will install a processing line at Experic’s cGMP facility in New Jersey to handle its thin-film freezing technology.

TFF Pharmaceuticals, a clinical-stage pharmaceutical company that specializes in developing and commercializing novel drug products using its thin-film freezing (TFF) technology, has expanded its engagement with contract manufacturing organization (CMO) Experic LLC. Under the agreement, Experic will install a TFF processing line at the company’s cGMP facility located in Cranbury, New Jersey.

According to the companies, installation of the custom-engineered equipment is expected to wrap in the early second quarter of 2021. The processing equipment installation will give TFF its third cGMP manufacturing location and increase its manufacturing capacity.

The TFF platform was created to help improve the solubility and absorption of poorly water-soluble drugs; according to the company, the technology is especially suited to generate dry-powder particles with properties targeted for inhalation delivery, especially to the deep lung, for respiratory therapies. The TFF process results in a “brittle matrix particle,” which reportedly possesses low bulk density, high surface area, and typically an amorphous morphology. allowing the particles to supersaturate when contacting the target site, such as lung tissue.

Glenn Mattes, CEO and president of TFF Pharmaceuticals, said the expansion of manufacturing operations at Experic provides the company with the capability to develop and produce products currently in assessment with various pharma companies.

“Experic has been a terrific partner for us because of their domain expertise in dry powder inhalation products,” Mattes commented. “They also provide us with unique downstream encapsulation technology that rounds out the specialized manufacturing requirements of our dry powder inhalation therapies.”

Jeffrey P. McMullen, CEO and chair of Experic, said the company is looking forward to working with TFF and supporting product development and manufacturing.

“We share their excitement in the continued advancement and expansion of their technology and business,” he commented.

Experic offers CMO and pharma supply services across a variety of dosing and packaging formats, including capsule filling, powder and pellet dosing (such as DPI), and autoinjectors and pen assemblies.